Where does Alamar Biosciences 's cash flow data come from?

Every line is extracted from Alamar Biosciences 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Alamar Biosciences ALMR Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26
Net income	-$21.33M-178%
Depreciation and amortization	$1.17M+31.4%
Stock-based compensation	$1.47M+137%
Change in accounts receivable	$6.85M+1,186%
Change in inventories	$1.27M-46.3%
Change in accounts payable	$1.34M+132%
Change in other assets	$327K+280%
Net cash from operating activities	-$20.35M-55.7%
Capital expenditures	$600K+8.3%
Net cash from investing activities	-$778K-105%
Proceeds from issuance of common stock	$1.8M+642%
Net cash from financing activities	$55.76M+22,847%
Effect of exchange rate changes on cash	-$52K-139%
Net increase (decrease) in cash	$34.58M+699%
Interest paid	$156K+5,100%
Accretion (Amortization) of Discounts and Premiums, Investments	——
Amortization expense related to capitalized debt issuance costs	$67K+59.5%
Convertible Note Issuance Costs Included In Net Income	$361K—
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	-$165K-223%
Increase (Decrease) in Contract with Customer, Asset	——
Increase Decrease In Net Investment In Sales Type Lease	——
Operating lease liabilities	-$1.09M-135%
Other current liabilities	-$1.23M+75.5%
Increase (Decrease) in Prepaid Expense and Other Assets	$1.96M+1,126%
Loss On Remeasurement Of Convertible Notes	$8.59M—
Operating lease right-of-use asset amortization	$461K-0.9%
Payments to Develop Software	$178K-58.4%
Proceeds from maturities of short-term investments	——
Payments Of Debt Issuance Costs	$324K—
Payments Of Stock Issuance Costs	$2.22M—
Deferred Financing And Deferred Offering Costs Included In Accrued Liabilities	$2.09M—
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	-$52K-139%
Equipment Transferred To Inventory	$214K+26.6%
Increase Decrease In Operating Lease Liability	-$1.09M-135%
Property And Equipment Included In Accounts Payable And Accrued Liabilities	$583K+27.6%
Vesting Of Early Exercised Stock Options	$102K+1,357%
Free cash flow	-$20.95M-53.8%
Free cash flow	-$20.95M-53.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Alamar Biosciences 's cash flow data come from?: Every line is extracted from Alamar Biosciences 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.